Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials.

Kodjikian L, Decullier E, Souied EH, Girmens JF, Durand EE, Chapuis FR, Huot L.

Graefes Arch Clin Exp Ophthalmol. 2014 Oct;252(10):1529-37. doi: 10.1007/s00417-014-2764-6. Epub 2014 Aug 22. Review.

2.

Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.

Chen G, Li W, Tzekov R, Jiang F, Mao S, Tong Y.

Retina. 2015 Feb;35(2):187-93. doi: 10.1097/IAE.0000000000000301.

PMID:
25105318
3.

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.

Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D'Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Mühlbauer B, Püntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G.

Cochrane Database Syst Rev. 2014 Sep 15;(9):CD011230. doi: 10.1002/14651858.CD011230.pub2. Review.

4.

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group.

Ophthalmology. 2013 Nov;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020. Epub 2013 Aug 2.

PMID:
23916488
5.

Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.

Berg K, Pedersen TR, Sandvik L, Bragadóttir R.

Ophthalmology. 2015 Jan;122(1):146-52. doi: 10.1016/j.ophtha.2014.07.041. Epub 2014 Sep 13.

PMID:
25227499
6.

Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration.

Johnson D, Sharma S.

Curr Opin Ophthalmol. 2013 May;24(3):205-12. doi: 10.1097/ICU.0b013e32835f8ec0. Review.

PMID:
23518613
7.

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC.

Ophthalmology. 2012 Jul;119(7):1399-411. doi: 10.1016/j.ophtha.2012.04.015. Epub 2012 May 11. Erratum in: Ophthalmology. 2012 Aug;119(8):1508. Ophthalmology. 2013 Sep;120(9):1719.

PMID:
22578446
8.

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.

Nguyen CL, Oh LJ, Wong E, Wei J, Chilov M.

BMC Ophthalmol. 2018 May 30;18(1):130. doi: 10.1186/s12886-018-0785-3.

9.

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.

Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF; Comparison of Age-related Macular Degeneration Treatments Trials Research Group.

Ophthalmology. 2013 Jan;120(1):122-9. doi: 10.1016/j.ophtha.2012.07.042. Epub 2012 Oct 6.

10.

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd.

Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1.

11.

Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.

Scott AW, Bressler SB.

Curr Opin Ophthalmol. 2013 May;24(3):190-6. doi: 10.1097/ICU.0b013e32835fefee. Review.

PMID:
23492430
12.

Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.

Schmid MK, Bachmann LM, Fäs L, Kessels AG, Job OM, Thiel MA.

Br J Ophthalmol. 2015 Feb;99(2):141-6. doi: 10.1136/bjophthalmol-2014-305149. Epub 2014 Jun 11. Review.

PMID:
25271911
13.

Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.

Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW.

Ophthalmology. 2014 Apr;121(4):936-45. doi: 10.1016/j.ophtha.2013.10.037. Epub 2014 Jan 7.

14.

Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.

Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB 3rd.

Am J Ophthalmol. 2013 Jul;156(1):23-28.e2. doi: 10.1016/j.ajo.2013.02.009. Epub 2013 May 8.

15.

Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration.

Kent JS, Iordanous Y, Mao A, Powell AM, Kent SS, Sheidow TG.

Can J Ophthalmol. 2012 Apr;47(2):159-64. doi: 10.1016/j.jcjo.2012.01.003.

PMID:
22560422
16.

Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.

Holekamp NM, Liu Y, Yeh WS, Chia Y, Kiss S, Almony A, Kowalski JW.

Am J Ophthalmol. 2014 Apr;157(4):825-833.e1. doi: 10.1016/j.ajo.2013.12.018. Epub 2013 Dec 31.

PMID:
24388973
17.
18.

Retinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumab.

Sizmaz S, Kucukerdonmez C, Kal A, Pinarci EY, Canan H, Yilmaz G.

Eur J Ophthalmol. 2014 Nov-Dec;24(6):904-10. doi: 10.5301/ejo.5000478. Epub 2014 May 5.

PMID:
24803153
19.

Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG; CATT Research Group.

Am J Ophthalmol. 2014 Jul;158(1):128-135.e10. doi: 10.1016/j.ajo.2014.04.004. Epub 2014 Apr 13.

20.

Switching intravitreal anti-VEGF treatment in neovascular age-related macular degeneration.

Küçükerdönmez C, Gelisken F, Yoeruek E, Bartz-Schmidt KU, Leitritz MA.

Eur J Ophthalmol. 2015 Jan-Feb;25(1):51-6. doi: 10.5301/ejo.5000480. Epub 2014 Jun 28.

PMID:
24980110

Supplemental Content

Support Center